Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 71

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Non-small cell lung cancer

Not recruiting

Study of Bemcentinib with Pembrolizumab, Carboplatin, and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with STK11 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Bergenbio ASA

Respiratory syncytial virus bronchiolitis

Not recruiting

Study on Preventing Respiratory Issues from RSV Bronchiolitis in Preterm Babies Using Palivizumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Palivizumab
  • Sponsor:Azienda Sanitaria Locale Della Provincia Di Biella

Cough

Not recruiting

Study on the Effectiveness and Safety of Camlipixant for Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Study on the Effects of Riociguat for Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Thoraxklinik Heidelberg gGmbH

Non-small cell lung cancer metastatic

Not recruiting

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Infantile apnoea+4

Not recruiting

Study on Automatic Oxygen Control for Extremely Preterm Infants Using Oxygen PH.EUR.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Oxygen Ph.eur.
  • Sponsor:Universitaetsklinikum Tuebingen AöR

B-cell lymphoma+8

Not recruiting

Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:CYC140 monohydrochloride monohydrate
  • Sponsor:Cyclacel Limited

Non-small cell lung cancer

Not recruiting

Study for Patients with Advanced Non-Small Cell Lung Cancer Worsened by Osimertinib Treatment, Using Selumetinib and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Conjunctivitis allergic+3

Not recruiting

Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allergen Extract From Dactylis Glomerata Pollen, Glutaraldehyde-Modified
  • Sponsor:Inmunotek S.L.

General physical health deterioration+1

Not recruiting

Study on Durvalumab for Patients with Poor General Condition and Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Non-small cell lung cancer stage III+2

Not recruiting

Study on Thoracic Radiotherapy and Durvalumab for Elderly or Frail Stage III Non-Small Cell Lung Cancer Patients Unable to Undergo Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Conjunctivitis allergic+3

Not recruiting

Study on the Effectiveness and Safety of Clustoid MM09 for Patients with Allergic Rhinitis or Rhinoconjunctivitis, with or without Mild to Moderate Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides Farinae Allergoid, Glutaraldehyde-Modified
  • Sponsor:Inmunotek S.L.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.